Co-Author
This page shows the publications co-authored by Kevin Elias and Neil Horowitz.
Connection Strength
7.652
-
Important insights for non-molar choriocarcinoma. BJOG. 2020 08; 127(9):1108.
Score: 0.869
-
Considering Changes in the Recommended Human Chorionic Gonadotropin Monitoring After Molar Evacuation. Obstet Gynecol. 2020 01; 135(1):9-11.
Score: 0.852
-
State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia. J Natl Compr Canc Netw. 2019 11 01; 17(11):1396-1401.
Score: 0.842
-
Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough? Gynecol Oncol. 2019 10; 155(1):1-2.
Score: 0.837
-
Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol. BMJ Open. 2022 Feb 24; 12(2):e059484.
Score: 0.247
-
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. Lancet Oncol. 2021 11; 22(11):1490-1491.
Score: 0.241
-
Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. Clinics (Sao Paulo). 2021; 76:e2830.
Score: 0.239
-
Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia. Reprod Sci. 2021 11; 28(11):3200-3211.
Score: 0.236
-
Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol. 2021 07; 86(1):e13394.
Score: 0.230
-
Outcomes of minimally invasive versus open abdominal hysterectomy in patients with gestational trophoblastic disease. Gynecol Oncol. 2021 02; 160(2):445-449.
Score: 0.227
-
Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. Am J Obstet Gynecol. 2021 04; 224(4):372.e1-372.e30.
Score: 0.224
-
Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol. 2020 12; 159(3):751-757.
Score: 0.224
-
EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. Gynecol Oncol. 2020 07; 158(1):99-104.
Score: 0.218
-
Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know? Int J Gynecol Cancer. 2018 05; 28(4):824-828.
Score: 0.190
-
Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1606-7.
Score: 0.160
-
Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1611.
Score: 0.160
-
Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer. Ann Surg Oncol. 2015 Apr; 22(4):1341-8.
Score: 0.148
-
ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene. 2022 Mar 18.
Score: 0.062
-
Clinical characteristics and thyroid function in complete hydatidiform mole complicated by hyperthyroidism. Gynecol Oncol. 2022 Apr; 165(1):137-142.
Score: 0.062
-
Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysis. Am J Obstet Gynecol. 2021 Oct 09.
Score: 0.060
-
Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia. Rev Bras Ginecol Obstet. 2021 Jul; 43(7):503-506.
Score: 0.060
-
Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right? Gynecol Oncol. 2021 09; 162(3):638-644.
Score: 0.059
-
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel). 2021 Jun 28; 13(13).
Score: 0.059
-
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 08; 22(8):1188-1198.
Score: 0.059
-
Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects. Int J Gynecol Cancer. 2021 09; 31(9):1299-1300.
Score: 0.059
-
Video Hysteroscopy in the Diagnosis of Molar Pregnancy in two Challenging Situations: Complete Mole with Normal hCG and Partial Mole with Early Gestational Age. J Minim Invasive Gynecol. 2021 08; 28(8):1448-1449.
Score: 0.057
-
Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. Best Pract Res Clin Obstet Gynaecol. 2021 Jul; 74:81-96.
Score: 0.057
-
When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia. Br J Cancer. 2021 03; 124(6):1033-1034.
Score: 0.057
-
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
Score: 0.056
-
Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study. Curr Probl Cancer. 2021 02; 45(1):100622.
Score: 0.055
-
Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. Clinics (Sao Paulo). 2020; 75:e1724.
Score: 0.055
-
How to optimize the management of gestational trophoblastic disease during the coronavirus disease era? Am J Obstet Gynecol. 2020 10; 223(4):604-605.
Score: 0.055
-
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol. 2020 08; 158(2):452-459.
Score: 0.055
-
Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. Int J Gynecol Cancer. 2020 09; 30(9):1366-1371.
Score: 0.055
-
Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2020 05; 157(2):372-378.
Score: 0.054
-
Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. Gynecol Oncol. 2020 03; 156(3):598-605.
Score: 0.053
-
Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol. 2019 05; 153(2):277-285.
Score: 0.050
-
Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study. J Med Internet Res. 2018 09 24; 20(9):e10897.
Score: 0.049
-
In Reply. Obstet Gynecol. 2018 07; 132(1):218.
Score: 0.048
-
Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstet Gynecol. 2018 04; 131(4):652-659.
Score: 0.047
-
Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? Gynecol Oncol. 2018 02; 148(2):239-246.
Score: 0.046
-
Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol. 2018 01; 148(1):5-11.
Score: 0.046
-
Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018 01; 148(1):161-167.
Score: 0.046
-
Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol. 2017 Apr; 145(1):88-95.
Score: 0.043
-
Gestational Trophoblastic Disease: Presentations from the XVIIIth World Congress on Gestational Trophoblastic Diseases. J Reprod Med. 2016 May-Jun; 61(5-6):185-6.
Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.